Skip to main content

Table 1 Hydroxychloroquine dosing pre-intervention versus post-intervention

From: The effect of an electronic medical record intervention on hydroxychloroquine prescribing habits and surveyed providers’ opinions of the 2016 American Academy of Ophthalmology guidelines in the rheumatology and dermatology practices of an academic institution

HCQ Dose (mg/kg/day) Pre-intervention Post-intervention
Rheumatology, n (%)
n = 1128
Dermatology, n (%)
n = 282
Rheumatology, n (%)
n = 1161
Dermatology, n (%)
n = 110
≤ 5.0 778 (68.9) 170 (60.3) 894 (77.0) 82 (74.5)
Female 626 (80.555.5) 122 (71.843.3) 708 (79.261.0) 56 (68.350.9)
 Lupusa 148 (23.613.1) 12 (9.8 (4.3) 79 (11.26.8) 9 (16.18.2)
 RA 201 (32.117.8) 0 133 (18.811.5) 0
Male 152 (19.513.5) 48 (28.217.0) 186 (20.816.0) 26 (31.723.6)
 Lupusa 16 (10.51.4) 10 (20.83.5) 11 (5.90.9) 6 (23.15.5)
 RA 64 (42.15.7) 0 55 (29.64.7) 0
5.1–6.5 277 (24.6) 78 (27.7) 222 (19.1) 22 (20.0)
Female 256 (92.422.7) 65 (83.323.0) 197 (88.717.0) 19 (86.417.3)
 Lupusa 70 (27.36.2) 10 (15.43.5) 20 (10.21.7) 3 (15.82.7)
 RA 61 (23.85.4) 0 38 (19.33.3) 0
Male 21 ((1.9)7.6) 13 (16.74.6) 25 (11.32.2) 3 (13.62.7)
 Lupusa 4 (19.00.35) 3 (23.11.1) 2 (0.10.2) 1 (33.30.9)
 RA 11 (52.40.98) 0 10 (0.40.9) 0
≥ 6.6 73 (6.5) 34 (12.1) 45 (3.9) 6 (5.5)
Female 70 (95.96.2) 32 (94.111.3) 42 (93.33.6) 4 (66.73.6)
 Lupusa 17 (24.31.5) 3 (9.41.1) 2 (4.80.2) 0
 RA 17 (24.31.5) 0 5 (11.90.4) 0
Male 3 (4.10.27) 2 (5.90.71) 3 (6.70.3) 2 (33.31.8)
 Lupusa 0 0 0 0
 RA 2 (66.70.18) 0 2 (66.70.2) 0
  1. RA rheumatoid arthritis
  2. a Includes systemic lupus erythematosus, discoid lupus, acute cutaneous lupus, glomerular disease associated with lupus